These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25177493)

  • 1. Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.
    Singh BH; Gulley JL
    Ther Adv Vaccines; 2014 Sep; 2(5):137-48. PubMed ID: 25177493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
    Madan RA; Gulley JL; Kantoff PW
    Cancer J; 2013; 19(1):50-8. PubMed ID: 23337757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
    Quinn DI; Shore ND; Egawa S; Gerritsen WR; Fizazi K
    Urol Oncol; 2015 May; 33(5):245-60. PubMed ID: 25575714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Era of Immunotherapy in Prostate Cancer.
    Pizzola C; Rizvi SM; Joshi M
    Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.
    Gulley JL; Madan RA; Pachynski R; Mulders P; Sheikh NA; Trager J; Drake CG
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-based therapies for metastatic prostate cancer: an update.
    Hossain MK; Nahar K; Donkor O; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(4):283-298. PubMed ID: 29421982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA; Elzey BD; Hahn NM
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for prostate cancer: recent developments and future challenges.
    Schweizer MT; Drake CG
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):641-55. PubMed ID: 24477411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
    Bilusic M; Heery C; Madan RA
    Vaccine; 2011 Sep; 29(38):6485-97. PubMed ID: 21741424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in metastatic prostate cancer.
    Slovin SF
    Indian J Urol; 2016; 32(4):271-276. PubMed ID: 27843208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic vaccines for prostate cancer: recent advances and future directions.
    Strauss J; Madan RA
    Expert Rev Vaccines; 2016 Jul; 15(7):907-14. PubMed ID: 26889831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer immunotherapy.
    Mitsogiannis I; Tzelves L; Dellis A; Issa H; Papatsoris A; Moussa M
    Expert Opin Biol Ther; 2022 May; 22(5):577-590. PubMed ID: 35037527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.